Literature DB >> 6268719

[Biological characterization including sensitivity to mitomycin C of cultured human ovarian cancers (author's transl)].

T Motoyama.   

Abstract

The present study first dealt with characterization of two cell lines, Kuramochi and CKS, established from human ovarian cancer. Secondary, the quantitative analyses of sensitivity of the cell lines to Mitomycin C was reported. The two cell lines showed typically epithelial features in vitro. Kuramochi cells, derived from undifferentiated carcinoma, had microvilli on the cell surface, cell continuity with the relative developed junctional complex, but no secretary granules and vesicles. The chromosomal analysis revealed the hyperdiploid modal number of 50. The population doubling time was about 26 hours. CKS cells, derived from serous cystadenocarcinoma, had secretary vesicles, microvilli, but no developed junctional complex. The chromosomal analysis reveals the hypodiploid modal number of 37. The population doubling time was about 34 hours. Biochemical markers of alpha-fetoprotein, human chorionic gonadotropin and carcinoembryonic antigen were not detected in both cell lines. 90% lethal dose of 2-hr-treatment with Mitomycin C was 0.42 microgram/ml in Kuramochi cell line and 1.13 microgram/ml in CKS cell line. These values were higher than the one of the control cell line, KATO-III, derived from signet-ring cell carcinoma of stomach. Ovarian cancers were suggested resistant to Mitomycin C.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6268719

Source DB:  PubMed          Journal:  Nihon Sanka Fujinka Gakkai Zasshi        ISSN: 0300-9165


  8 in total

1.  Model Cell Lines and Tissues of Different HGSOC Subtypes Differ in Local Estrogen Biosynthesis.

Authors:  Renata Pavlič; Marija Gjorgoska; Tea Lanišnik Rižner
Journal:  Cancers (Basel)       Date:  2022-05-24       Impact factor: 6.575

2.  Experiments with tissue cultures from a human ovarian serous cystadenocarcinoma producing cancer antigen 125 (CA125), tissue polypeptide antigen (TPA) and carcinoembryonic antigen (CEA).

Authors:  I Fukazawa; N Inaba; Y Ota; N Sato; S Shirotake; H Iwasawa; S Sekiya; H Takamizawa; N Suzuki; H Tokita
Journal:  Arch Gynecol Obstet       Date:  1988       Impact factor: 2.344

3.  Evaluating cell lines as tumour models by comparison of genomic profiles.

Authors:  Silvia Domcke; Rileen Sinha; Douglas A Levine; Chris Sander; Nikolaus Schultz
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

4.  Sequential azacitidine and carboplatin induces immune activation in platinum-resistant high-grade serous ovarian cancer cell lines and primes for checkpoint inhibitor immunotherapy.

Authors:  Michelle W Wong-Brown; Andre van der Westhuizen; Nikola A Bowden
Journal:  BMC Cancer       Date:  2022-01-24       Impact factor: 4.430

Review 5.  Three-Dimensional Modelling of Ovarian Cancer: From Cell Lines to Organoids for Discovery and Personalized Medicine.

Authors:  Christine Yee; Kristie-Ann Dickson; Mohammed N Muntasir; Yue Ma; Deborah J Marsh
Journal:  Front Bioeng Biotechnol       Date:  2022-02-10

6.  Integrated Genomic, Epigenomic, and Expression Analyses of Ovarian Cancer Cell Lines.

Authors:  Eniko Papp; Dorothy Hallberg; Gottfried E Konecny; Daniel C Bruhm; Vilmos Adleff; Michaël Noë; Ioannis Kagiampakis; Doreen Palsgrove; Dylan Conklin; Yasuto Kinose; James R White; Michael F Press; Ronny Drapkin; Hariharan Easwaran; Stephen B Baylin; Dennis Slamon; Victor E Velculescu; Robert B Scharpf
Journal:  Cell Rep       Date:  2018-11-27       Impact factor: 9.423

7.  Metabolism of Estrogens: Turnover Differs Between Platinum-Sensitive and -Resistant High-Grade Serous Ovarian Cancer Cells.

Authors:  Stefan Poschner; Judith Wackerlig; Dan Cacsire Castillo-Tong; Andrea Wolf; Isabel von der Decken; Tea Lanišnik Rižner; Renata Pavlič; Anastasia Meshcheryakova; Diana Mechtcheriakova; Monika Fritzer-Szekeres; Theresia Thalhammer; Walter Jäger
Journal:  Cancers (Basel)       Date:  2020-01-23       Impact factor: 6.639

8.  WNT signaling inducing activity in ascites predicts poor outcome in ovarian cancer.

Authors:  Anna Kotrbová; Petra Ovesná; Tomáš Gybel'; Tomasz Radaszkiewicz; Markéta Bednaříková; Jitka Hausnerová; Eva Jandáková; Luboš Minář; Igor Crha; Vít Weinberger; Luděk Záveský; Vítězslav Bryja; Vendula Pospíchalová
Journal:  Theranostics       Date:  2020-01-01       Impact factor: 11.556

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.